design and results of persist-1 trial of pacritinib for myelofibrosis
Published 9 years ago • 81 plays • Length 2:04Download video MP4
Download video MP3
Similar videos
-
1:45
design and results of pacritinib for myelofibrosis trial (persist-1)
-
3:46
results of the phase iii persist-1 trial of pacritinib for myelofibrosis
-
2:18
updates on persist-1 trial of pacritinib for myelofibrosis
-
2:18
results of persist-1 & persist-2 studies of pacritinib vs best alternative therapy in myelofibrosis
-
0:54
study design for persist-2 and other upcoming trials of pacritinib
-
30:48
designing proof-of-concept clinical trials - ashwin gollerkeri, m.d., pfizer
-
3:19
first-line treatment selection in myelofibrosis
-
23:37
pearl study overview: a mayo clinic research study
-
1:42
consistency of pacritinib in patients with mf: pooled analysis from persist-1 & persist-2
-
2:19
insights into the phase iia mylox-1 trial: assessing efficacy of gb2064 in myelofibrosis
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
5:12
ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
1:34
pelabresib in myelofibrosis: the manifest trials
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
1:45
results of the phase 3 persist-1 trial of pacritinib for myelofibrosis
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
1:15
potential approval of pacritinib for the treatment of myelofibrosis
-
1:31
promising agents under investigation for the treatment of myelofibrosis with cytopenia
-
1:52
an update on the use of navtemadlin in myelofibrosis
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
3:48
jak inhibition for the early treatment of myelofibrosis